UC-514321

UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity In Vitro UC-514321 increases apoptosis in AML cells not in normal HSPCs. UC-514321 (0-500 nM, 48 h) inhibits AML cells viability TET1-signaling dependently. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MONOMAC-6, THP-1, KOCL-48, KASUMI-1, ML-2, and NB4 cells. Concentration: 0-500 nM. Incubation Time: 48 hours. Result: Most significantly repressed MONOMAC-6 cell viability. Showed no inhibitory effect on the viability of TET1-low AML. RT-PCRCell Line: MONOMAC-6 cells. Concentration: 0-500 nM. Incubation Time: 48 hours. Result: Functioned as TET1-transcription inhibitors in TET1-high AMLs and their anti-leukemic effects are TET1-dependent. In Vivo UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MLL-AF9-AML mice and AE9a-AML model . Dosage: 2.5 mg/kg. Administration: IP., once per day, for 10 days. Result: Showed an improved therapeutic effect in AML mouse models in vivo. Prolonged the median survival over three fold. Form:Solid IC50& Target:STAT3 STAT5 TET1

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet